

Un Jung Kang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5253396/publications.pdf>

Version: 2024-02-01

136
papers

10,755
citations

26630

56
h-index

33894

99
g-index

144
all docs

144
docs citations

144
times ranked

11302
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>mTOR</scp> Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis. <i>Movement Disorders</i> , 2022, 37, 778-789.	3.9	16
2	Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 253-263.	3.9	16
3	Reply to: "Letter on Discussion of Gait Research". <i>Movement Disorders</i> , 2022, 37, 1328-1328.	3.9	0
4	Mitophagy deficiency increases NLRP3 to induce brown fat dysfunction in mice. <i>Autophagy</i> , 2021, 17, 1205-1221.	9.1	53
5	COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 3-8.	2.8	21
6	Î±-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. <i>Acta Neuropathologica</i> , 2021, 142, 495-511.	7.7	80
7	Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. <i>Movement Disorders</i> , 2021, 36, 2444-2446.	3.9	24
8	A rapid Î±-synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 374-384.	3.7	40
9	High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 179.	5.2	86
10	Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of <scp>Leucine-Rich Repeat Kinase 2</scp> Carriers: A Novel <scp>Enzyme-Linked Immunosorbent Assay-Based Method. <i>Movement Disorders</i> , 2020, 35, 2095-2100.	3.9	24
11	Exercise Reverses Dysregulation of T-Cell-Related Function in Blood Leukocytes of Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 10, 1389.	2.4	6
12	Impact of the <scp>COVID-19</scp> Pandemic on Parkinson's Disease and Movement Disorders. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 357-360.	1.5	37
13	Impact of the <scp>COVID-19</scp> Pandemic on Parkinson's Disease and Movement Disorders. <i>Movement Disorders</i> , 2020, 35, 711-715.	3.9	134
14	Reversibility of Tardive Dyskinesia Syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 4, 282.	2.0	7
15	Alterations in the intrinsic properties of striatal cholinergic interneurons after dopamine lesion and chronic L-DOPA. <i>ELife</i> , 2020, 9, .	6.0	32
16	Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 178-183.	2.2	20
17	Effects of repeated waist-pull perturbations on gait stability in subjects with cerebellar ataxia. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2019, 16, 50.	4.6	10
18	Comparative study of cerebrospinal fluid Î±-synuclein seeding aggregation assays for diagnosis of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 536-544.	3.9	146

#	ARTICLE	IF	CITATIONS
19	<i>SMPD1</i> mutations, activity, and α -synuclein accumulation in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 526-535.	3.9	81
20	Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5108-5117.	7.1	136
21	Mitochondrial dysfunction and mitophagy defect triggered by heterozygous <i>GBA</i> mutations. <i>Autophagy</i> , 2019, 15, 113-130.	9.1	155
22	CSF β -amyloid ₄₂ and risk of freezing of gait in early Parkinson disease. <i>Neurology</i> , 2019, 92, e40-e47.	1.1	45
23	Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 11.	5.3	169
24	Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 989-994.	1.9	56
25	Alpha galactosidase A activity in Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 112, 85-90.	4.4	56
26	Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 49-54.	2.2	61
27	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.1	23
28	Posters presentation selected for the blue ribbon session at the annual meeting of the Parkinson's disease and movement disorders society (Hong Kong, October, 2018).. <i>Movement Disorders</i> , 2018, 33, 1977-1991.	3.9	0
29	Hoehn and Yahr stage 3 and postural stability item in the movement disorder society's "unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2018, 33, 1188-1189.	3.9	3
30	Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation. <i>Stroke</i> , 2018, 49, 1977-1980.	2.0	2
31	Reply To: <sc>D</sc>etection of <sc>A</sc>lpha<sc>S</sc>yuclein in <sc>S</sc>aliva: <sc>T</sc>he <sc>I</sc>mportance of <sc>P</sc>reanalytical <sc>A</sc>ssessment. <i>Movement Disorders</i> , 2018, 33, 1031-1031.	3.9	1
32	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. <i>Movement Disorders</i> , 2018, 33, 282-288.	3.9	122
33	Dopamine neuron glutamate cotransmission evokes a delayed excitation in lateral dorsal striatal cholinergic interneurons. <i>ELife</i> , 2018, 7, .	6.0	49
34	Evoked transients of pH-sensitive fluorescent false neurotransmitter reveal dopamine hot spots in the globus pallidus. <i>ELife</i> , 2018, 7, .	6.0	12
35	Frequency of <i>GBA</i> Variants in Autopsy-Proven Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 574-581.	1.5	47
36	<sc>C</sc>omments on the recent viewpoint article on low-frequency deep brain stimulation for <sc>P</sc>arkinson's disease. <i>Movement Disorders</i> , 2017, 32, 176-176.	3.9	5

#	ARTICLE	IF	CITATIONS
37	Adaptation of Stability during Perturbed Walking in Parkinson's Disease. <i>Scientific Reports</i> , 2017, 7, 17875.	3.3	33
38	Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis. <i>PLoS ONE</i> , 2017, 12, e0172348.	2.5	69
39	Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 663-672.	1.7	57
40	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. <i>Movement Disorders</i> , 2016, 31, 924-932.	3.9	48
41	SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, .	5.3	36
42	Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. <i>Npj Parkinson's Disease</i> , 2015, 1, 15007.	5.3	26
43	Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. <i>Movement Disorders</i> , 2015, 30, 1862-1869.	3.9	5
44	Balancing the basal ganglia circuitry: A possible new role for dopamine D2 receptors in health and disease. <i>Movement Disorders</i> , 2015, 30, 895-903.	3.9	43
45	Enhanced histamine H2 excitation of striatal cholinergic interneurons in l-DOPA-induced dyskinesia. <i>Neurobiology of Disease</i> , 2015, 76, 67-76.	4.4	37
46	Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. <i>Neurology</i> , 2015, 84, 415-420.	1.1	132
47	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015, 132, 96-168.	5.7	379
48	Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 7.	5.2	74
49	Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. <i>Neurology</i> , 2015, 85, 557-557.	1.1	7
50	Striatal cholinergic interneuron regulation and circuit effects. <i>Frontiers in Synaptic Neuroscience</i> , 2014, 6, 22.	2.5	173
51	DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. <i>Neurology</i> , 2014, 82, 636-637.	1.1	9
52	Striatal Cholinergic Cell Ablation Attenuates l-DOPA Induced Dyskinesia in Parkinsonian Mice. <i>Journal of Neuroscience</i> , 2014, 34, 3090-3094.	3.6	68
53	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	9.0	312
54	Loss of PINK1 Attenuates HIF-1 α Induction by Preventing 4E-BP1-Dependent Switch in Protein Translation under Hypoxia. <i>Journal of Neuroscience</i> , 2014, 34, 3079-3089.	3.6	37

#	ARTICLE	IF	CITATIONS
55	Parkinson's Disease Biomarkers: Resources for Discovery and Validation. <i>Neuropsychopharmacology</i> , 2014, 39, 241-242.	5.4	8
56	Reversibility of tardive dyskinesia syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 282.	2.0	3
57	Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. <i>Acta Neuropathologica</i> , 2013, 126, 671-682.	7.7	76
58	The role of neuroplasticity in dopaminergic therapy for Parkinson disease. <i>Nature Reviews Neurology</i> , 2013, 9, 248-256.	10.1	67
59	Pink1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced akt and increased p38 mapk activation, and downregulation of egfr. <i>Glia</i> , 2013, 61, 800-812.	4.9	81
60	Activity enhances dopaminergic long-duration response in Parkinson disease. <i>Neurology</i> , 2012, 78, 1146-1149.	1.1	26
61	Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1015-1017.	1.9	81
62	Role of DaTSCAN and clinical diagnosis in Parkinson disease. <i>Neurology</i> , 2012, 79, 1744-1744.	1.1	7
63	Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2012, 2, 321-331.	2.8	161
64	Diagnostic biomarkers of Parkinson's disease: what gain at what cost?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 769-769.	1.9	3
65	The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells. <i>Mitochondrion</i> , 2011, 11, 707-715.	3.4	47
66	Transcription factor AP-2 β regulates the neurotransmitter phenotype and maturation of chromaffin cells. <i>Molecular and Cellular Neurosciences</i> , 2011, 46, 245-251.	2.2	15
67	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. <i>Annals of Neurology</i> , 2011, 69, 570-580.	5.3	371
68	Enhanced striatal cholinergic neuronal activity mediates DOPA-induced dyskinesia in parkinsonian mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 840-845.	7.1	166
69	Dopamine-dependent motor learning: Insight into levodopa's long-duration response. <i>Annals of Neurology</i> , 2010, 67, 639-647.	5.3	85
70	Structural determinants of PINK1 topology and dual subcellular distribution. <i>BMC Cell Biology</i> , 2010, 11, 90.	3.0	29
71	DJ-1 and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. <i>Brain</i> , 2010, 133, 713-726.	7.6	575
72	Biomarkers in neuropsychiatric diseases. <i>Neurobiology of Disease</i> , 2009, 35, 115-116.	4.4	0

#	ARTICLE	IF	CITATIONS
73	Consideration of gene therapy for paediatric neurotransmitter diseases. <i>Journal of Inherited Metabolic Disease</i> , 2009, 32, 387-394.	3.6	3
74	Characterization of PINK1 processing, stability, and subcellular localization. <i>Journal of Neurochemistry</i> , 2008, 106, 464-474.	3.9	216
75	Regulation of the Noradrenaline Neurotransmitter Phenotype by the Transcription Factor AP-2 β . <i>Journal of Biological Chemistry</i> , 2008, 283, 16860-16867.	3.4	35
76	Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice. <i>Journal of Neuroscience</i> , 2008, 28, 425-433.	3.6	211
77	A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. <i>Journal of Neurosurgery</i> , 2008, 109, 405-409.	1.6	90
78	Effects of Low to Moderate Acute Doses of Pramipexole on Impulsivity and Cognition in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 45-51.	1.4	85
79	Neuroprotective effect of the surfactant poloxamer 188 in a model of intracranial hemorrhage in rats. <i>Journal of Neurosurgery: Pediatrics</i> , 2007, 106, 36-40.	1.3	21
80	Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. <i>Human Molecular Genetics</i> , 2007, 16, 2900-2910.	2.9	89
81	Expansion of the first PolyA tract of <i>ARX</i> causes infantile spasms and status dystonicus. <i>Neurology</i> , 2007, 69, 427-433.	1.1	143
82	Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. <i>Journal of Neurochemistry</i> , 2007, 104, 071018045431005-???	3.9	68
83	MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9. <i>Brain Research</i> , 2007, 1182, 1-10.	2.2	18
84	Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2007, 27, 11-23.	4.4	59
85	Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. <i>Journal of Neurochemistry</i> , 2006, 97, 1467-1480.	3.9	137
86	Stromal Cell-Derived Inducing Activity, Nurr1, and Signaling Molecules Synergistically Induce Dopaminergic Neurons from Mouse Embryonic Stem Cells. <i>Stem Cells</i> , 2006, 24, 557-567.	3.2	97
87	Neural Precursors Derived from Embryonic Stem Cells, but Not Those from Fetal Ventral Mesencephalon, Maintain the Potential to Differentiate into Dopaminergic Neurons After Expansion In Vitro. <i>Stem Cells</i> , 2006, 24, 1583-1593.	3.2	70
88	Behavioral models of Parkinson's disease in rodents: A new look at an old problem. <i>Movement Disorders</i> , 2006, 21, 1595-1606.	3.9	200
89	Identification and Treatment of Cervical and Oromandibular Dystonia in Acutely Brain-Injured Patients. <i>Neurocritical Care</i> , 2005, 3, 139-145.	2.4	20
90	Age-dependent Motor Deficits and Dopaminergic Dysfunction in DJ-1 Null Mice. <i>Journal of Biological Chemistry</i> , 2005, 280, 21418-21426.	3.4	221

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------

91	Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from		
----	--	--	--

#	ARTICLE	IF	CITATIONS
109	The Localization and Functional Contribution of Striatal Aromatic L-Amino Acid Decarboxylase to L-3,4-Dihydroxyphenylalanine Decarboxylation in Rodent Parkinsonian Models. <i>Cell Transplantation</i> , 2000, 9, 567-576.	2.5	20
110	Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system. <i>Brain Research</i> , 2000, 873, 203-211.	2.2	14
111	Vesicular Monoamine Transporter-2 and Aromatic L-Amino Acid Decarboxylase Enhance Dopamine Delivery after L-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats. <i>Journal of Neuroscience</i> , 1999, 19, 3266-3274.	3.6	46
112	Gene therapy for Parkinson's disease: review and update. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1551-1564.	4.1	1
113	Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. <i>Neuroscience</i> , 1999, 88, 617-628.	2.3	220
114	In Vivo L-DOPA Production by Genetically Modified Primary Rat Fibroblast or 9L Gliosarcoma Cell Grafts via Coexpression of GTP Cyclohydrolase I with Tyrosine Hydroxylase. <i>Experimental Neurology</i> , 1998, 151, 249-264.	4.1	53
115	The Role of Glutathione in Dopaminergic Neuronal Survival. <i>Journal of Neurochemistry</i> , 1997, 69, 1850-1858.	3.9	80
116	Role of Aromatic L-Amino Acid Decarboxylase for Dopamine Replacement by Genetically Modified Fibroblasts in a Rat Model of Parkinson's Disease. <i>Journal of Neurochemistry</i> , 1997, 69, 2055-2063.	3.9	49
117	Double Transduction with GTP Cyclohydrolase I and Tyrosine Hydroxylase Is Necessary for Spontaneous Synthesis of L-DOPA by Primary Fibroblasts. <i>Journal of Neuroscience</i> , 1996, 16, 4449-4456.	3.6	112
118	Spread of symptoms in idiopathic torsion dystonia. <i>Movement Disorders</i> , 1995, 10, 143-152.	3.9	161
119	Brain-derived neurotrophic factor-transduced fibroblasts: Production of BDNF and effects of grafting to the adult rat brain. <i>Journal of Comparative Neurology</i> , 1995, 354, 361-376.	1.6	71
120	Genetic Modification of Cells with Retrovirus Vectors for Grafting into the Central Nervous System. <i>Journal of Neuroscience</i> , 1995, 15, 211-237.		7
121	Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. <i>Journal of Neuroscience</i> , 1995, 15, 7810-7820.	3.6	252
122	Structure of the Rat Aromatic L-Amino Acid Decarboxylase Gene: Evidence for an Alternative Promoter Usage. <i>Journal of Neurochemistry</i> , 1993, 60, 1058-1064.	3.9	38
123	Regulation of dopamine production by genetically modified primary fibroblasts. <i>Journal of Neuroscience</i> , 1993, 13, 5203-5211.	3.6	84
124	DOPA-decarboxylation in the striata of rats with unilateral substantia nigra lesions. <i>Neuroscience Letters</i> , 1992, 147, 53-57.	2.1	32
125	Intracerebral grafting in the dopaminergic system: issues and controversy. <i>Current Opinion in Neurobiology</i> , 1991, 1, 414-419.	4.2	3
126	Distant effects of locally injected botulinum toxin: A double-blind study of single fiber EMG changes. <i>Muscle and Nerve</i> , 1991, 14, 672-675.	2.2	167

#	ARTICLE	IF	CITATIONS
127	Cellular replacement therapy for neurologic disorders: potential of genetically engineered cells. Journal of Cellular Biochemistry, 1991, 45, 252-257.	2.6	40
128	Letters to the editor. Movement Disorders, 1990, 5, 178-183.	3.9	16
129	Letters to the editor. Movement Disorders, 1990, 5, 352-355.	3.9	48
130	Deduced amino acid sequence of bovine aromatic l-amino acid decarboxylase: homology to other decarboxylases. Molecular Brain Research, 1990, 8, 83-87.	2.3	48
131	Dopamine beta-hydroxylase activity in cerebrospinal fluid of idiopathic torsion dystonia. Neurology, 1990, 40, 1626-1626.	1.1	3
132	Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. Movement Disorders, 1989, 4, 157-175.	3.9	139
133	Case 1, 1989: Juvenile-onset parkinsonism, dystonia, and pyramidal tract signs. Movement Disorders, 1989, 4, 363-370.	3.9	5
134	Natural history and treatment of tardive dystonia. Movement Disorders, 1986, 1, 193-208.	3.9	268
135	A case of parkinsonism following striatal lacunar infarction.. Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 1087-1088.	1.9	41
136	Trophic factor delivery by gene therapy. , 0, , 532-547.		0